DelveInsight's "Focal Segmental Glomerulosclerosis (FSGS) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Focal Segmental Glomerulosclerosis (FSGS), historical and forecasted epidemiology as well as the Focal Segmental Glomerulosclerosis (FSGS) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Focal Segmental Glomerulosclerosis (FSGS) market report provides current treatment practices, emerging drugs, Focal Segmental Glomerulosclerosis (FSGS) market share of the individual therapies, current and forecasted Focal Segmental Glomerulosclerosis (FSGS) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Focal Segmental Glomerulosclerosis (FSGS) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Study Period: 2017-2030
Focal segmental glomerulosclerosis (FSGS) is a well-defined histologic pattern of injury characterized by sclerosis, hyalinosis, foam-cell infiltration, vacuolization of podocytes, and podocyte precursor proliferation between glomeruli tuft and Bowman’s capsule.The use of the word “focal” signifies that in FSGS, only some glomeruli are sclerosed, and “segmental” means that only a portion of the affected glomerulus is affected. It typically presents with nephrotic syndrome with characterized proteinuria and, obliteration or failure of glomerular capillary loops by increased extracellular matrix in glomeruli capillary tufts.
FSGS is one of the most common causes of primary glomerular disease in children and adults, which may progress to end-stage renal disease (ESRD) with a relatively high risk. Commonly, it is divided into primary (idiopathic) and secondary FSGS. Primary FSGS sometimes has no identifiable cause or known etiology, and it is linked to genetic mutations in podocyte-specific proteins, whereas, secondary FSGS may occur in response to previous glomerular injury, glomerular hypertension, hypertrophy, drug toxicity, some malignancies or viral infections, obesity, and reduced renal mass. The clinical features of FSGS are the features of nephrotic syndrome and include peripheral edema, marked proteinuria, hypertension, hypoalbuminemia, hyperlipidemia, and progressive loss of renal function.
FSGS is further classified as collapsing, tip, cellular, perihilar, and not otherwise specified variants according to the location and character of the sclerotic lesion. Also, primary or idiopathic FSGS is considered to be related to podocyte injury, and the pathogenesis of podocyte injury has been actively investigated. Disease presentation and associated medical conditions are beneficial to distinguish between primary and secondary FSGS. Conditions, such as infections, hypertension, and obesity, as well as proteinuria that is within nephrotic range but not accompanied by the full-blown nephrotic syndrome are suggestive of secondary FSGS.
Focal segmental glomerulosclerosis (FSGS) Diagnosis and Treatment
It covers the details of conventional and current medical therapies and diagnosis available in the Focal segmental glomerulosclerosis (FSGS) market for the treatment of the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.
The DelveInsight Focal segmental glomerulosclerosis (FSGS) market report gives a thorough understanding of FSGS symptoms by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides FSGS symptoms of treatment algorithms and treatment guidelines for FSGS symptoms in the US, Europe, and Japan.
The Focal Segmental Glomerulosclerosis (FSGS) epidemiology division provide insights about historical and current Focal Segmental Glomerulosclerosis (FSGS) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Focal Segmental Glomerulosclerosis (FSGS) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
Country Wise- Focal Segmental Glomerulosclerosis (FSGS) Epidemiology
The epidemiology segment also provides the Focal Segmental Glomerulosclerosis (FSGS) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The drug chapter segment of the Focal segmental glomerulosclerosis (FSGS) report encloses the detailed analysis of FSGS marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Focal segmental glomerulosclerosis (FSGS) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Currently, there are no FDA-approved therapies for FSGS. The therapeutic market size of FSGS in the US is mainly accounted for the off-label treatment options, such as non-immune therapy in conjunction with immunotherapy.
Products detail in the report…
Focal Segmental Glomerulosclerosis (FSGS) Emerging Drugs
Sparsentan: Retrophin
Sparsentan is a novel investigational, dual mechanism of action that acts as potent angiotensin receptor blocker (ARB) and strongly selective endothelin receptor (ETA) antagonist, with in vitro selectivity toward endothelin receptor type A. It has also received orphan drug designation for FSGS from both FDA and EMA. Currently, it is in the phase III development for the FSGS.
Products detail in the report…
The Focal Segmental Glomerulosclerosis (FSGS) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Focal Segmental Glomerulosclerosis (FSGS) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a thorough detail of Focal Segmental Glomerulosclerosis (FSGS) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, Focal Segmental Glomerulosclerosis (FSGS) market in 7MM is expected to change in the study period 2017-2030.
Key Findings
This section includes a glimpse of the Focal segmental glomerulosclerosis (FSGS) market in 7MM. The market size of FSGS in the seven major markets was found to be USD 286.40 million in 2017.
The United States Market Outlook
This section provides the total Focal segmental glomerulosclerosis (FSGS) market size and market size by therapies in the United States.
The United States accounts for the highest market size of FSGS in comparison to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan. FSGS in the US is mainly accounted for the off-label treatment options, such as non-immune therapy in conjunction with immunotherapy. The non-immune therapy includes the control of blood pressure, lipids, and weight by using angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARB) while the immunotherapy includes, corticosteroids (Prednisone), calcineurin inhibitors (Cyclosporine and Tacrolimus), Mycophenolate Mofetil, and Biologics (Rituximab), as well as Plasma exchange for those seriously ill patients. Moreover, in case of medication failure, dialysis and kidney transplant become the next treatment options. Despite these available treatments, the management of FSGS remains a challenge due to the complex causes of disease and dense pathogenesis.
EU-5 Countries: Market Outlook
The total Focal segmental glomerulosclerosis (FSGS) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
There is a lack of approved therapy for the treatment of Focal segmental glomerulosclerosis (FSGS), management of FSGS depends on the use of off label medications in Europe. Regardless of all available treatments, there is unsatisfied patients’ outcome under the current treatments, therefore, innovation are encouraged on the treatment strategy based on Kidney Disease, Improving Global Outcomes guideline, and international collaborations are required for the potential novel immunosuppressive or immunomodulatory therapies.
Japan Market Outlook
The total Focal Segmental Glomerulosclerosis (FSGS) market size and market size by therapies in Japan is also mentioned.
This section focusses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2017–2030. The analysis covers Focal segmental glomerulosclerosis (FSGS) market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.
The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Focal segmental glomerulosclerosis (FSGS) key players involved in developing targeted therapeutics.
Major players include: Retrophin, Dimerix, Aurinia Pharmaceuticals, Complexa, Bristol-Myers Squibb, Reata Pharmaceuticals/ Kyowa Kirin, Astellas Pharma/Kyowa Kirin, Pfizer, Chemocentryx, ZyVersa Therapeutics and others. Currently, Sparsentan (Retrophin) designation will give an advantage in both the US and EU markets and is expected to get launch in 2022.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Focal Segmental Glomerulosclerosis (FSGS) emerging therapies.
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
According to USRDS statistics, costs of dialysis provided by Medical Centers have been estimated to exceed those in private settings, in part because patients had more comorbidities, outpatient and emergency visits, prescriptions, and longer hospital stays.
To keep up with current market trends, we take KOLs and SME's opinion working in Focal Segmental Glomerulosclerosis (FSGS) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Focal Segmental Glomerulosclerosis (FSGS) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
We perform Competitive and Market Intelligence analysis of the Focal Segmental Glomerulosclerosis (FSGS) Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.
Market Insights:
Epidemiology Insights:
What is Focal Segmental Glomerulosclerosis (FSGS)?
The United States accounts for the largest Immune Thrombocytopenia (ITP) market size in the 7MM.
What was the Focal Segmental Glomerulosclerosis (FSGS) market size in the major markets?
As per DelveInsight assessments, FSGS market size in the 7MM was found to USD 333.36 Million in 2017.
Which geography accounted for the lowest Focal Segmental Glomerulosclerosis (FSGS) market size?
In the EU5, the market size of FSGS in Germany had the highest market size with USD 28.86 million in 2017, while Spain had the lowest market size of FSGS in 2017.
What are the upcoming therapies in the Focal Segmental Glomerulosclerosis market?
Novel therapies such as Sparsentan (Retrophin), DMX-200 (Dimerix), Voclosporin (Aurinia Pharmaceuticals), CXA-10 (Complexa), Abatacept (Bristol-MyersSquibb), Bardoxolone methyl (Reata Pharmaceuticals/ Kyowa Kirin) are in the Focal segmental glomerulosclerosis pipeline.
Which are the leading companies in Focal Segmental Glomerulosclerosis (FSGS) market?
Several companies are working robustly to develop novel therapies such as Sparsentan (Retrophin), DMX-200 (Dimerix), Voclosporin (Aurinia Pharmaceuticals), CXA-10 (Complexa), Abatacept (Bristol-MyersSquibb), Bardoxolone methyl (Reata Pharmaceuticals/ Kyowa Kirin).
How is epidemiology segmented for Focal Segmental Glomerulosclerosis (FSGS)?
Focal segmental glomerulosclerosis epidemiology is segmented into total prevalent cases, gender-specific, age-specific, and type-specific prevalent cases in the 7MM (2017-28).
1. Key Insights
2. Executive Summary of Focal Segmental Glomerulosclerosis (FSGS)
3. Competitive Intelligence Analysis for Focal Segmental Glomerulosclerosis (FSGS)
4. Focal Segmental Glomerulosclerosis (FSGS): Market Overview at a Glance
4.1. Focal Segmental Glomerulosclerosis (FSGS) Total Market Share (%) Distribution in 2017
4.2. Focal Segmental Glomerulosclerosis (FSGS) Total Market Share (%) Distribution in 2030
5. Focal Segmental Glomerulosclerosis (FSGS): Disease Background and Overview
5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis
6. Patient Journey
7. Focal Segmental Glomerulosclerosis (FSGS) Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Focal Segmental Glomerulosclerosis (FSGS) Epidemiology Scenario in the 7MM (2017-2030)
7.4. United States Epidemiology
7.4.1. Focal Segmental Glomerulosclerosis (FSGS) Epidemiology Scenario in the United States (2017-2030)
7.5. EU-5 Country-wise Epidemiology
7.5.1. Germany Epidemiology
7.5.1.1. Focal Segmental Glomerulosclerosis (FSGS) Epidemiology Scenario in Germany (2017-2030)
7.5.2. France Epidemiology
7.5.2.1. Focal Segmental Glomerulosclerosis (FSGS) Epidemiology Scenario in France (2017-2030)
7.5.3. Italy Epidemiology
7.5.3.1. Focal Segmental Glomerulosclerosis (FSGS) Epidemiology Scenario in Italy (2017-2030)
7.5.4. Spain Epidemiology
7.5.4.1. Focal Segmental Glomerulosclerosis (FSGS) Epidemiology Scenario in Spain (2017-2030)
7.5.5. United Kingdom Epidemiology
7.5.5.1. Focal Segmental Glomerulosclerosis (FSGS) Epidemiology Scenario in the United Kingdom (2017-2030)
7.5.6. Japan Epidemiology
7.5.6.1. Focal Segmental Glomerulosclerosis (FSGS) Epidemiology Scenario in Japan (2017-2030)
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Focal Segmental Glomerulosclerosis (FSGS) Treatment and Management
8.2. Focal Segmental Glomerulosclerosis (FSGS) Treatment Algorithm
9. Unmet Needs
10. Key Endpoints of Focal Segmental Glomerulosclerosis (FSGS) Treatment
11. Marketed Products
11.1. List of Marketed Products in the 7MM
11.2. Drug Name: Company Name
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal Clinical Trials
11.2.5. Summary of Pivotal Clinical Trial
List to be continued in report
12. Emerging Therapies
12.1. Key Cross
12.2. Drug Name: Company Name
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
List to be continued in report
13. Focal Segmental Glomerulosclerosis (FSGS): Seven Major Market Analysis
13.1. Key Findings
13.2. Focal Segmental Glomerulosclerosis (FSGS) Market Size in 7MM
13.3. Focal Segmental Glomerulosclerosis (FSGS) Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
15.1. United States: Market Size
15.1.1. Focal Segmental Glomerulosclerosis (FSGS) Total Market Size in the United States
15.1.2. Focal Segmental Glomerulosclerosis (FSGS) Market Size by Therapies in the United States
15.2. EU-5 countries: Market Size and Outlook
15.3. Germany Market Size
15.3.1. Focal Segmental Glomerulosclerosis (FSGS) Total Market Size in Germany
15.3.2. Focal Segmental Glomerulosclerosis (FSGS) Market Size by Therapies in Germany
15.4. France Market Size
15.4.1. Focal Segmental Glomerulosclerosis (FSGS) Total Market Size in France
15.4.2. Focal Segmental Glomerulosclerosis (FSGS) Market Size by Therapies in France
15.5. Italy Market Size
15.5.1. Focal Segmental Glomerulosclerosis (FSGS) Total Market Size in Italy
15.5.2. Focal Segmental Glomerulosclerosis (FSGS) Market Size by Therapies in Italy
15.6. Spain Market Size
15.6.1. Focal Segmental Glomerulosclerosis (FSGS) Total Market Size in Spain
15.6.2. Focal Segmental Glomerulosclerosis (FSGS) Market Size by Therapies in Spain
15.7. United Kingdom Market Size
15.7.1. Focal Segmental Glomerulosclerosis (FSGS) Total Market Size in the United Kingdom
15.7.2. Focal Segmental Glomerulosclerosis (FSGS) Market Size by Therapies in the United Kingdom
15.8. Japan Market Outlook
15.8.1. Japan Market Size
15.8.2. Focal Segmental Glomerulosclerosis (FSGS) Total Market Size in Japan
15.8.3. Focal Segmental Glomerulosclerosis (FSGS) Market Size by Therapies in Japan
16. Access and Reimbursement Overview of Focal Segmental Glomerulosclerosis (FSGS)
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
*The table of contents is not exhaustive; the final content may vary.
List of Tables:
Table 1: List of organization
Table 3: Characteristic clinical and pathology features of the six forms of FSGS
Table 4: Causes of focal segmental glomerulosclerosis
Table 5: Genes related to FSGS or nephrotic syndrome
Table 6: Diagnostic protein biomarker candidates for FSGS
Table 7: Prognostic candidate biomarkers
Table 8: Differential diagnoses of FSGS
Table 9: Prevalent Population of Focal Segmental Glomerulosclerosis in 7MM (2017–2030)
Table 10: Prevalent Cases of FSGS in the United States (2017–2030)
Table 11: Gender-specific cases of FSGS in the United States (2017–2030)
Table 12: Type-specific Cases of FSGS in the United States (2017–2030)
Table 13: Prevalent Cases of FSGS in Germany (2017–2030)
Table 14: Gender-specific cases of FSGS in Germany (2017–2030)
Table 15: Type-specific Cases of FSGS in Germany (2017–2030)
Table 16: Prevalent Cases of FSGS in France (2017–2030)
Table 17: Gender-specific cases of FSGS in France (2017–2030)
Table 18: Type-specific Cases of FSGS in France (2017–2030)
Table 19: Prevalent Cases of FSGS in Italy (2017–2030)
Table 20: Gender-specific cases of FSGS in Italy (2017–2030)
Table 21:Type-specific Cases of FSGS in Italy (2017–2030)
Table 22: Prevalent Cases of FSGS in Spain (2017–2030)
Table 23: Gender-specific cases of FSGS in Spain (2017–2030)
Table 24: Type-specific Cases of FSGS in Spain (2017–2030)
Table 25: Prevalent Cases of FSGS in the United Kingdom (2017–2030)
Table 26: Gender-specific cases of FSGS in the United Kingdom (2017–2030)
Table 27: Type-specific Cases of FSGS in the UK (2017–2030)
Table 28: Prevalent Cases of FSGS in Japan (2017–2030)
Table 29: Gender-specific cases of FSGS in Japan (2017–2030)
Table 30: Type-specific Cases of FSGS in Japan (2017–2030)
Table 31: Pharmacologic therapies for FSGS
Table 32: KDIGO Definitions in Adult FSGS
Table 33: KDIGO Guideline: Idiopathic FSGS in adults
Table 34: Emerging Drugs Analysis-Key cross comparison
Table 35: Sparsentan, Clinical Trial Description, 2020
Table 36: DMX-200, Clinical Trial Description, 2020
Table 37: Voclosporin Clinical Trial Description, 2020
Table 38: CXA-10, Clinical Trial Description, 2020
Table 39: Abatacept, Clinical Trial Description, 2020
Table 40: Bardoxolone methyl, Clinical Trial Description, 2020
Table 41: Bleselumab, Clinical Trial Description, 2020
Table 42: CCX140-B, Clinical Trial Description, 2020
Table 43: PF-06730512, Clinical Trial Description, 2020
Table 44: 7 Major Market Size of Focal Segmental Glomerulosclerosis in USD Million (2017–2030)
Table 45: United States Market Size of FSGS, in USD Million (2017–2030)
Table 46: Market Size of FSGS by Therapies in USD Million (2017–2030)
Table 47: Germany Market Size of FSGS, in USD Million (2017–2030)
Table 48: Market Size of FSGS by Therapies in USD Million (2017–2030)
Table 49: France Market Size of FSGS, in USD Million (2017–2030)
Table 50: Market Size of FSGS by Therapies in USD Million (2017–2030)
Table 51: Italy, Market Size of FSGS, in USD Million (2017–2030)
Table 52: Market Size of FSGS by Therapies in USD Million (2017–2030)
Table 53: Spain, Market Size of FSGS, in USD Million (2017–2030)
Table 54: Market Size of FSGS by Therapies in USD Million (2017–2030)
Table 55: UK Market Size of FSGS, in USD Million (2017–2030)
Table 56: Market Size of FSGS by Therapies in USD Million (2017–2030)
Table 57: Japan, Market Size of FSGS, in USD Million (2017–2030)
Table 58:Market Size of FSGS by Therapies in USD Million (2017–2030)
List of Figues:
Figure 1: Epidemiology and Market Methodology
Figure 2: Focal Segmental Glomerulosclerosis
Figure 3: Common symptoms of FSGS
Figure 4: Histopathology of minimal change disease and focal segmental glomerulosclerosis
Figure 5: Pathogenesis of FSGS
Figure 6: Prevalent Population of Focal Segmental Glomerulosclerosis in 7MM (2017–2030)
Figure 7: Prevalent Cases of FSGS in the United States (2017–2030)
Figure 8: Gender-specific Prevalent Cases of FSGS in the US (2017–2030)
Figure 9: Type-specific Diagnosed Prevalent Cases of FSGS in the US (2017–2030)
Figure 10: Prevalent Cases of FSGS in Germany (2017–2030)
Figure 11: Gender-specific of FSGS in Germany (2017–2030)
Figure 12: Type-specific Cases of FSGS in Germany (2017–2030)
Figure 13: Prevalent Cases of FSGS in France (2017–2030)
Figure 14: Gender-specific Cases of FSGS in France (2017–2030)
Figure 15: Type-specific Cases of FSGS in France (2017–2030)
Figure 16: Prevalent Cases of FSGS in Italy (2017–2030)
Figure 17: Gender-specific Cases of FSGS in Italy (2017–2030)
Figure 18: Type-specific Cases of FSGS in Italy (2017–2030)
Figure 19: Prevalent Cases of FSGS in Spain (2017–2030)
Figure 20: Gender-specific Cases of FSGS in Spain (2017–2030)
Figure 21: Type-specific Cases of FSGS in Spain (2017–2030)
Figure 22: Prevalent Cases of FSGS in the United Kingdom (2017–2030)
Figure 23: Gender-specific Cases of FSGS in the United Kingdom (2017–2030)
Figure 24: Type-specific Cases of FSGS in the UK (2017–2030)
Figure 25: Prevalent Cases of FSGS in Japan (2017–2030)
Figure 26: Gender-specific Cases of FSGS in Japan (2017–2030)
Figure 27: Type-specific Cases of FSGS in Japan (2017–2030)
Figure 28: A Treatment algorithm of FSGS
Figure 29: Unmet Needs
Figure 30: Seven Major Market Size of Focal Segmental Glomerulosclerosis in USD Million (2017–2030)
Figure 31: Market Size of FSGS in the United States, USD Millions (2017–2030)
Figure 32: Market Size of FSGS by Therapies in USD Million (2017–2030)
Figure 33: Market Size of FSGS in Germany, USD Millions (2017–2030)
Figure 34: Market Size of FSGS by Therapies in USD Million (2017–2030)
Figure 35: Market Size of FSGS in France, USD Millions (2017–2030)
Figure 36: Market Size of FSGS by Therapies in USD Million (2017–2030)
Figure 37: Market Size of FSGS in Italy, USD Millions (2017–2030)
Figure 38: Market Size of FSGS by Therapies in USD Million (2017–2030)
Figure 39: Market Size of FSGS in Spain, USD Millions (2017–2030)
Figure 40: Market Size of FSGS by Therapies in USD Million (2017–2030)
Figure 41: Market Size of FSGS in the UK, USD Millions (2017–2030)
Figure 42: Market Size of FSGS by Therapies in USD Million (2017–2030)
Figure 43: Market Size of FSGS in Japan, USD Millions (2017–2030)
Figure 44:Market Size of FSGS by Therapies in USD Million (2017–2030)
Figure 45:Market Drivers
Figure 46:Market Barriers
